AN2 Therapeutics, Inc.(ANTX)

Biotechnology · Menlo Park, CA

$5.39-0.22 (-3.92%)

Delayed quote: Oct 6, 2026, 9:30 AM EDT

EBITDA Yield: N/A

Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The EBITDA yield is N/A as of 2026-10-06T13:30:31.956Z.

Stored calculation inputs

Calculation as of: 2026-10-06T13:30:31.956Z.

Quote observation: 2026-10-06T13:30:00.000Z. Amounts in USD. The price header may show a later quote.

TTM operating EBITDA · period ending 2026-06-30: -38,811,000
Quote market capitalization: 194,127,119
Total debt · period ending 2026-06-30: 0
Cash · period ending 2026-06-30: 44,318,000

FMP input reference: 66e3eaee1cdd755dffe0dd2f4d89b3fc137545160e5faabf240127d9674bae42

EV/EBITDA|Earnings Yield|OCF Yield|FCF Yield|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

ANTX EBITDA Yield Metrics

EBITDA YIELD

N/A

ANTX Competitors' EBITDA Yield

ANTX

AN2 Therapeutics, Inc.

Current

Market Cap

$194.13M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ELDN

Eledon Pharmaceuticals, Inc.

vs ANTX

Market Cap

$195.29M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DERM

Journey Medical Corporation

vs ANTX

Market Cap

$184.12M

EBITDA Yield

0.69%

TTM Avg

0.65%

3Y Avg

2.68%

5Y Avg

2.68%

ETRA

Electra Therapeutics Inc.

vs ANTX

Market Cap

$205.34M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CNTN

Canton Strategic Holdings Inc

vs ANTX

Market Cap

$180.47M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CMPX

Compass Therapeutics, Inc.

vs ANTX

Market Cap

$178.29M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DTIL

Precision BioSciences, Inc.

vs ANTX

Market Cap

$178.17M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CUE

Cue Biopharma, Inc.

vs ANTX

Market Cap

$175.94M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CHRS

Coherus Oncology, Inc.

vs ANTX

Market Cap

$174.59M

EBITDA Yield

N/A

TTM Avg

12.03%

3Y Avg

9.31%

5Y Avg

9.31%

CGEN

Compugen Ltd.

vs ANTX

Market Cap

$219.36M

EBITDA Yield

N/A

TTM Avg

17.11%

3Y Avg

12.89%

5Y Avg

12.89%

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
AN2 Therapeutics, Inc. (ANTX)	$194.13M	N/A	N/A	N/A	N/A
Eledon Pharmaceuticals, Inc. (ELDN)vs ›	$195.29M	N/A	N/A	N/A	N/A
Journey Medical Corporation (DERM)vs ›	$184.12M	0.69%	0.65%	2.68%	2.68%
Electra Therapeutics Inc. (ETRA)vs ›	$205.34M	N/A	N/A	N/A	N/A
Canton Strategic Holdings Inc (CNTN)vs ›	$180.47M	N/A	N/A	N/A	N/A
Compass Therapeutics, Inc. (CMPX)vs ›	$178.29M	N/A	N/A	N/A	N/A
Precision BioSciences, Inc. (DTIL)vs ›	$178.17M	N/A	N/A	N/A	N/A
Cue Biopharma, Inc. (CUE)vs ›	$175.94M	N/A	N/A	N/A	N/A
Coherus Oncology, Inc. (CHRS)vs ›	$174.59M	N/A	12.03%	9.31%	9.31%
Compugen Ltd. (CGEN)vs ›	$219.36M	N/A	17.11%	12.89%	12.89%

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EBITDA Yield: N/A

ANTX EBITDA Yield Metrics

ANTX Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics